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Abstract
Background: Viral load (VL) monitoring is the standard of care in developing country settings for detecting HIV treatment
failure. Since 2010 the World Health Organization has recommended a phase-in approach to VL monitoring in resource-
limited settings. We conducted a systematic review of the accuracy and precision of HIV VL technologies for treatment
monitoring.
Methods and Findings: A search of Medline and Embase was conducted for studies evaluating the accuracy or
reproducibility of commercially available HIV VL assays. 37 studies were included for review including evaluations of the
Amplicor Monitor HIV-1 v1.5 (n = 25), Cobas TaqMan v2.0 (n = 11), Abbott RealTime HIV-1 (n = 23), Versant HIV-1 RNA bDNA
3.0 (n = 15), Versant HIV-1 RNA kPCR 1.0 (n = 2), ExaVir Load v3 (n = 2), and NucliSens EasyQ v2.0 (n = 1). All currently available
HIV VL assays are of sufficient sensitivity to detect plasma virus levels at a lower detection limit of 1,000 copies/mL. Bias data
comparing the Abbott RealTime HIV-1, TaqMan v2.0 to the Amplicor Monitor v1.5 showed a tendency of the Abbott
RealTime HIV-1 to under-estimate results while the TaqMan v2.0 overestimated VL counts. Compared to the Amplicor
Monitor v1.5, 2–26% and 9–70% of results from the Versant bDNA 3.0 and Abbott RealTime HIV-1 differed by greater than
0.5log10. The average intra and inter-assay variation of the Abbott RealTime HIV-1 were 2.95% (range 2.0–5.1%) and 5.44%
(range 1.17–30.00%) across the range of VL counts (2log10–7log10).
Conclusions: This review found that all currently available HIV VL assays are of sufficient sensitivity to detect plasma VL of
1,000 copies/mL as a threshold to initiate investigations of treatment adherence or possible treatment failure. Sources of
variability between VL assays include differences in technology platform, plasma input volume, and ability to detect HIV-1
subtypes. Monitoring of individual patients should be performed on the same technology platform to ensure appropriate
interpretation of changes in VL. Prospero registration # CD42013003603.
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Introduction
As of mid 2013 it is estimated that over nine million HIV
infected individuals are on antiretroviral therapy (ART) world-
wide and a substantial proportion have been on treatment for ten
years or more [1]. As the global ART cohort continues to expand
and mature, the need for ongoing monitoring is becoming
increasingly important to ensure treatment efficacy and minimize
the risk of HIV drug resistance. Clinical and immunological
monitoring techniques have poor sensitivity and specificity for
detecting virologic failure, leading to a substantial misclassification
of treatment responses, resulting in delayed switching in some
cases and inappropriate switching from first line regimens in others
[2–7].
Routine HIV viral load (VL) monitoring has the potential to
improve the accuracy of diagnosis of treatment failure, enable
more targeted adherence interventions, and preserve the efficacy
of ART [8]. Monitoring HIV VL is often not performed in
resource-limited settings because the assays are costly, and require
sophisticated, expensive laboratory equipment and trained tech-
nicians [9,10]. Despite these limitations, the importance of HIV
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VL testing is increasingly recognized: in 2010 the World Health
Organization (WHO) recommended that countries begin to phase
in VL for monitoring patients on ART [1], a recommendation
reinforced in the 2013 treatment guidelines [11]. Detailed
descriptions of available VL technologies can be found in a
UNITAID HIV/AIDS diagnostic landscaping [12].
In order to support decisions regarding which VL tools to phase
in, we conducted a systematic review of the performance and
operational characteristics of commercially available HIV VL
assays.
Methods
We first verified that no systematic reviews had already been
conducted on this topic by searching the Cochrane Library and
Centre for Reviews and Dissemination, University of York and
National Institute for Health Research. A research protocol was
then developed following standard guidance [13] and this was
reviewed by all members of the HIV Monitoring Technologies
Working Group before the search was performed. The systematic
review protocol was registered with PROSPERO (http://www.
crd.york.ac.uk/PROSPERO), registration number
CD42013003603.
Search
Medline and Embase were searched using the search terms
(‘HIV-1’ or ‘HIV-2’ or ‘HIV’ or ‘human immunodeficiency virus’
or ‘HIV type 1’ or ‘HIV type 2’ or ‘human immunodeficiency
virus type 1’ or ‘human immunodeficiency virus type 2’) and (‘viral
load’ or ‘viral RNA’) and (‘compar*’ or ‘eval*’) and (‘measur*’ or
‘quant*’ or ‘technol*’ or ‘test’) and (‘accuracy’ or ‘performance’ or
‘precision’ or ‘sensitivity’ or ‘specificity’ or ‘sensitivity and
specificity’). Results of the search were exported to EndNote X3,
duplicates removed and the remainder assessed for relevance and
fulfillment of the selection criteria.
Study Selection
The search was conducted in February 2010 and updated in
April 2012 to include scientific research articles published in peer-
reviewed journals, in English, between January 1990 and the
search date. Publications evaluating or comparing the perfor-
mance of commercial assays for the quantification of HIV-1 or
HIV-2 virus load in plasma were included in the search.
There were no limitations on the method of nucleic acid
extraction, amplification, or detection but the assays under
investigation had to be commercially available at the time of the
review. The study population was limited to adults but no
restriction was placed on the geographical origin of the samples or
the HIV subtype (HIV-1 or HIV-2). Publications using samples
from standardized panels were also considered for inclusion
providing they met the study criteria. No authors were contacted
for further information and all data presented in this review were
available in the included publications.
Data collection processes
Two independent reviewers extracted data on assay accuracy
and reproducibility from publications meeting the inclusion
criteria as defined in the protocol. Where there was any
discrepancy, the reviewers met to discuss the difference and came
to a consensus on inclusion or exclusion from the study. The
quality of publications included in the HIV VL review was scored
using adapted STARD guidelines [14,15]. This included questions
on the title and abstract; introduction; methods including
participant/sample characteristics, test methods and statistical
methods; results including data on participants and test results;
and discussion (Annex S3). The two reviewers selected 17 critical
quality criteria of the original 23 which were more appropriate for
evaluations of quantitative assays.
Quantitative data synthesis
Accuracy and reproducibility data were summarized graphically
in Excel. Accuracy measures included bias and limits of agreement
[16], sensitivity and specificity, and the percentage of results
differing by 0.5Log10, which is generally considered the clinically
relevant difference between two VL measurements [17,18].
Reproducibility measures included within- and between-assay
variability, reported as % coefficient of variation (%CV).
Results
Study selection
The search produced 1,715 titles, of which 580 were removed as
duplicates. Of the remaining 1,135 titles and abstracts, 261
publications were reviewed as full text, and 37 met the criteria for
inclusion and were taken forward for inclusion in the review
(Figure 1) [19–55].
Study characteristics
The studies included data on the following assays: Roche
Amplicor Monitor v1.5 (Amplicor 1.5) (n = 25), Roche Cobas
TaqMan v2.0 (TaqMan v2.0) (n = 11), Abbott RealTime HIV-1
(Abbott RealTime) (n = 23), Versant HIV-1 RNA bDNA 3.0
(bDNA 3.0) (n = 15), Versant HIV-1 RNA kPCR 1.0 (kPCR 1.0)
(n = 2), Cavidi ExaVir Load v3 (ExaVir v3) (n = 2) and the
NucliSens EasyQ 2.0 (EasyQ 2.0) (n = 1). Only one publication
evaluated assays using HIV-2 samples (29) and the remainder used
HIV-1 Group M, N, and O. There was no single standard
reference test used as a comparator in all studies. Of the 37
included studies, 12 were published in 2009 (median), with a
minimum and maximum of 2000 and 2012 respectively.
Quantitative Data Synthesis: Accuracy of HIV VL Assays
Analytical Sensitivity and Specificity of HIV VL Assays
with Plasma. One study provided analytical sensitivity and
specificity data for ExaVir Load v3 compared to Amplicor
Monitor v1.5 [28] (Table 1). Sensitivity of the ExaVir v3 was 96–
100% at HIV VL concentrations above 2000 copies/mL, but
decreases to 59% when VL concentration decreased to between
50–400 copies/mL. The specificity of the ExaVir v3 was evaluated
using HIV-1 negative samples and reported as 100% [26].
Five studies evaluated the specificity of the Amplicor v1.5,
Abbott RealTime, bDNA 3.0, and ExaVir v3 assays using HIV-1
negative samples and reported as 100% [15,18,28,45,49]. When
tested with a panel containing four HIV-2, four HCV, and four
polyomavirus BK plasma samples, the specificity of the kPCR was
92% [39]. One study evaluated the specificity of the TaqMan v2.0
using HIV-1 negative samples containing potentially cross-reactive
reactive viruses (including adenovirus Type 5, cytomegalovirus,
Epstein-Barr virus, hepatitis B, C, and A viruses, herpes simplex
virus Type I and Type II and others (n = 660) and found no false
positive results or cross-reactivity [44].
Clinically important differences in result. Seventeen
studies evaluated the percentage of results differing by a clinically
important value, defined as 0.5log10, between the index test and
reference test [22,27–29,31,38–41,45,48–51,55]. Data were avail-
able for Amplicor v1.5, TaqMan v2, Abbott RealTime, bDNA
3.0, kPCR, and ExaVir v3.
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Between 8.5% [49] and 70.0% [38] of results provided by the
Abbott RealTime assay differed by greater than 0.5log10
compared to the Roche Monitor v1.5 (Figure 2). The greatest
differences in results occurred using the 1 mL Abbott RealTime
sample input, where 70% of results differed by more than 0.5log10
compared to the Amplicor 1.5 [38]. Results from the bDNA 3.0
showed much lower levels of discordance compared to the
Amplicor 1.5, with between 2–26% of results having clinically
Figure 1. HIV VL Search Algorithm.
doi:10.1371/journal.pone.0085869.g001
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important differences [22,27]. Only one study reported differences
between results from the ExaVir v3.0 and the Amplicor v1.5; in
this study, 27% of results from the ExaVir differed by more than
0.5log10 [28].
When comparing the assays to the Abbott RealTime assy,
between 10 and 30% of TaqMan results [41,51], and 13% of
bDNA v3 results [48] differed by more than 0.5log10.
Bias. Bias was measured between an index test and the
Amplicor v1.5 as a reference standard in 14 publications
[19,24,25,29,37,38,40,41,43,45,46,48,52,55]. These included
comparisons with the Abbott RealTime (n= 11)
[19,25,29,38,40,45,46,48,55], TaqMan v2.0 (n = 4) [24,25,41],
and bDNA 3.0 (n= 4) [37,43,52]. There were no bias data
available comparing the ExaVir v3, EasyQ v2.0, or the kPCR to
the Monitor v1.5. Figure 3 summarizes the range of bias
measurements reported and the variability in the limits of
agreement reported for each assay when evaluated alongside the
Amplicor v1.5.
The EasyQ reports results as IU/mL (International Units/mL).
A conversion factor supplied by the manufacturer was applied to
enable comparison with other studies; however this process did not
produce consistent results when applied to the limits of agreement.
Data on bias were also available comparing index tests to the
Abbott RealTime (Figure 4) [19,29,30,32,35,39,41,42,45,48,53],
TaqMan v2.0 (Figure 5) [24,30,35,41,42,50,51,54] and to a WHO
International Standard (Table 2) [51]. Compared to the Abbott
RealTime, the Taqman v2.0 overestimated VL counts by 0.04–
0.33 log10 c/mL [30,35,41,42], while the ExaVir v3 and kPCR
underestimated VL but only by 0.28 and 0.16 log10c/mL,
respectively [32,39]. The limits of agreement associated with the
ExaVir v3 spanned from 21.27 to 0.72 log10c/mL [32], and those
associated with the kPCR data point from20.474 to 0.154 log10c/
mL [39]. When index tests were compared to the TaqMan v2.0,
the kPCR underestimated VL [50]. The Abbott RealTime both
over and under-estimated HIV VL values but never by more than
0.5log10 [30,35,41,42,51]), with the exception of one study that
reported limits of agreement spanning from 21 to 0.6 log10 c/mL
[42]. EasyQ 2.0 overestimated VL by 0.88log10 c/mL [54].
Finally, when compared to the WHO International Standard,
neither the Abbott RealTime nor the TaqMan v2.0 differed by
more than 0.5log10 with the Abbott RealTime displaying slight
overestimation while the TaqMan v2.0 showed slight underesti-
mation of HIV VL [51]).
Quantitative Data Synthesis: Precision of HIV VL Assays
Data on intra-assay (within-run) and inter-assay (between-run)
variability were reported for six assays: Amplicor v1.5 [23,47],
Abbott RealTime (Figure 6) [19,20,23,38,40,45], and the kPCR
(Figure 7) [39,50]. The Abbott RealTime showed excellent intra-
and inter-assay reproducibility (,10% variability) at low copy
Table 1. Analytical Sensitivity of the ExaVir Load v3
compared to Amplicor Monitor v1.5.
Cut-off (copies/mL) Publication N Sensitivity
.200 (28) 199 92%
.400 (28) 178 94%
.1000 (28) 145 98%
.5000 (28) 23 100%
50–400 (28) 64 59%
401–2000 (28) 57 86%
2001–10 000 (28) 50 96%
10 001–50 000 (28) 48 100%
doi:10.1371/journal.pone.0085869.t001
Figure 2. % of results differing by .0.5log10 between index test and Amplicor v1.5 (data extracted from references [22,27–
29,38,40,45,48,49,55]). *No volume specified.
doi:10.1371/journal.pone.0085869.g002
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Figure 3. Bias between Index Test and Ampicor v1.5 as a comparator (data extracted from references
[19,24,25,29,37,38,40,41,43,45,46,48,52,55]). *No volume specified.
doi:10.1371/journal.pone.0085869.g003
Figure 4. Bias between Index Test and Abbott RealTime as a comparator (data extracted from references [19,30,32,35,39,41,42,48]).
doi:10.1371/journal.pone.0085869.g004
Systematic Review of Viral Load Technologies
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numbers. One study, however, found the inter-assay variability to
be 30% at 500 000 c/mL [19]. The kPCR showed overall intra-
and inter-assay variability exceeding 15% [39,50].
Quality Assessment of Studies Included in the HIV VL
Review
All thirty-seven articles included in the review were assessed for
quality by two independent reviewers (Annex S1, S2). No article
met all 17 quality assessment criteria. The quality scores ranged
from 24–94%, and the median was 65%. While 95% of articles
described the study aims, only 8% reported on staff training.
Twenty-three (62%) and twenty-six (70%) of included publications
clearly described sample acquisition and sample storage condi-
tions, respectively. Twenty-one studies (57%) detailed the statistics
performed but only 16 (43%) presented descriptive statistics and
bias calculations. All studies discussed the clinical relevance of
their findings.
Discussion
In 2013, the World Health Organization recommended that,
with the exception of dried blood spot samples, the threshold for
detection of virological failure should be lowered to 1000 c/mL.
This recommendation was made in support of a shift towards a
more strategic use of antiretrovirals both for the treatment of HIV
infection and also the prevention of onward transmission through
earlier initiation of ART among priority groups such as pregnant
women and serodiscordant couples [11].
This review found that all the assays currently in use can reliably
detect HIV VL of 1000 c/mL, which is within the linear ranges of
VL assays claimed by manufacturers (Table 3). If a threshold of
$1000 c/mL is used to consider switching to a second line
regimen, then all assays were found to have acceptable perfor-
mance to be of use in clinical decision making. The challenge of
routinely and reliably detecting 1000 c/mL may be of greater
concern for the next generation of point-of-care tests.
The most difficult aspect of conducting this review was the
different reference standards used for evaluating test performance
in different studies. For comparability it would be useful if a single
standard measurement was used for HIV VL. The NucliSens
EasyQ is the only assay to report results using IU/mL. As
technologies evolve, a consensus international standard for HIV
VL copies that is widely accessible would provide a valid and
easier reference standard for determining the analytical perfor-
mance of a new assay.
Sources of variability between VL assays reported include not
only differences in technology platform, but also plasma input
volume, and ability to detect HIV-1 subtypes. VL monitoring
should therefore be performed on the same technology platform
for monitoring individual patients to ensure appropriate interpre-
tation of changes in VL, unless clinically relevant differences are
not identified between different assays.
Figure 5. Bias between Index Test and TaqMan v2.0 as a comparator (data extracted from references [30,35,41,42,50,51,54]). *No
volume specified.
doi:10.1371/journal.pone.0085869.g005
Table 2. Bias data between index test and WHO International Standard [50].
Index Test
Reference Standard (mean log
copies/ml) Bias Limits of Agreement (min) Limits Of Agreement (max)
Abbott RealTime HIV-1 WHO International Standard Low
(2.29)
20.3 20.44 20.16
Abbott RealTime HIV-1 WHO International Standard High
(4.38)
20.26 20.31 20.21
Roche TaqMan v2.0 WHO International Standard Low
(2.30)
0.31 0.22 0.39
Roche TaqMan v2.0 WHO International Standard High
(4.40)
0.17 0.1 0.23
doi:10.1371/journal.pone.0085869.t002
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Interpretation of the data available was also limited by the
variable quality of the publications. This review highlights the
need for more rigor in the design and reporting of evaluations of
HIV VL quantification technologies, particularly as new versions
of HIV VL assays and point-of-care (POC) formats become
available. One shortcoming highlighted by the review is the
incorrect application of statistical techniques. Correlation and
linear regression were the most common measurements reported
but bias and limits of agreement would be much more informative.
Unlike linear regression, Bland-Altman plots describe the mean
difference between two sets of data points and give this value a
direction indicating whether the index test is likely to under- or
over-quantify results [16]. As with CD4 quantification technolo-
gies, the extent of misclassification above and below a clinically
important threshold will need to be investigated [56]. It is
important for future studies to report the frequency, intensity and
direction of the misclassifications [1], because misclassification can
have clinical and public health implications (patients are left on
failing regimens and may develop drug resistance) and economic
implications (second line regimens are often expensive and options
beyond second-line are limited). Precision or reproducibility
should also be detailed with a clear description of how the
measures were obtained, including information on number of
samples, number of replicates per sample, and a descriptive
summary of the characteristics of the samples used including mean
HIV VL (6 SD) and range. The results of the review show that
standardized practices and guidelines for improved methods
undertaking and reporting evaluations of HIV VL assay evalua-
tions are needed, particularly with respect to defining the study
population, reporting algorithms for inclusion and exclusion of
samples throughout the study, reporting training of technicians,
and the use of appropriate statistical methods [11].
The main limitation of this review methodology is that the
inclusion criteria were limited to studies published in English,
which may have overlooked useful data available in other
languages.
Since the results of our review indicate that all currently
commercially available HIV VL assays can provide a reliably
accurate measure of plasma VL $1000 c/mL, switching from the
current WHO recommended threshold of 5,000 c/mL for
investigations for treatment compliance or possible treatment
failure to 1,000 c/mL would allow earlier detection of treatment
failure, enable more targeted adherence interventions, and
preserve the efficacy of ART. Choice of technology platform
should take into account the ability to detect HIV-1 subtypes in
the target population. Serial samples for VL monitoring need to be
performed on the same technology platform for proper interpre-
tation of any meaningful changes in VL.
Figure 6. Intra- and inter-assay variation for the Abbott
RealTime HIV-1(plasma) according to log copy number/mL of
sample (data extracted from references [19,20,23,38,40,45]).
doi:10.1371/journal.pone.0085869.g006
Figure 7. Intra- and inter-assay variation for the Versant kPCR
(plasma) according to log copy number/mL of sample (data
extracted from references [39,50]).
doi:10.1371/journal.pone.0085869.g007
Table 3. Manufacturer Data: Plasma Input Volume and Linear Range of Detection.
Manufacturer: Assay Input vol Linear Range (c/ml)
Abbott RealTime HIV-1 0.2 mL 0.2 mL sample input: 150–10,000,000
0.5 mL 0.5 mL sample input: 75–10,000,000
0.6 mL 0.6 mL sample input: 40–10,000,000
1.0 mL 1.0 mL sample input:40–10,000,000
bioMe´rieux NucliSens EasyQ HIV-1 v2.0 0.1 mL 10–10,000,000
Cavidi ExaVir Load 1 mL 200–600,000
Roche Diagnostics Cobas Amplicor HIV-1 MONITOR TEST, v1.5 0.5 mL Standard protocol: 400–750,000
Ultra-sensitive protocol: 50–100,000
Roche COBAS AmpliPre/COBAS TaqMan HIV-1 Test, v2.0 1 mL 20–100,000,000
Siemens VERSANT HIV-1 RNA 3.0 assay (bDNA) 1.0 mL 50–500,000
Siemens VERSANT HIV-1 RNA 1.0 assay (kPCR) 0.65 mL 37–11,000,000
doi:10.1371/journal.pone.0085869.t003
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